Bluestem Capital

Leveraging a proprietary, minimally invasive anterior delivery platform, TherOptix seeks to improve treatment outcomes by optimally targeting diseased tissue with effective molecules across a range of indications and molecule classes. Equinox is a medical device company with an adjustable, non-surgical, non-pharmacological technology to treat diseases of the optic nerve such as glaucoma, idiopathic intracranial hypertension (IIH), hypotony, visual impairment and intracranial pressure (VIIP). It has also received early funding commitments from leading ophthalmology experts, and a grant from NASA/NSBRI as part of the Vision For Mars program. Presbyopia is the gradual loss of an eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide. Quick installation of universal hardware/software bundle provides immediate savings in water and energy with added protection against variable feed water quality. EDCO’s Solarity® software provides point of care batch scanning and indexing of patient medical records that complements electronic health record systems. Technology from neurolens is only available to Independent Eye Care Providers. Hubble Therapeutics (Hubble TX) is a developer of a gene therapy intended for pediatric patients with the retinal blinding disease.